论文部分内容阅读
目的:为多囊脂质体在递药系统中的应用提供参考。方法:以“多囊脂质体”“multivesicular liposomes”等为关键词,在中国知网、Pub Med等数据库中查阅1983-2013年的相关文献,对多囊脂质体作为药物载体在递药系统的研究情况进行归纳与总结。结果与结论:共查询到文献609篇,其中有效文献20篇。经分析表明,多囊脂质体为非同心腔室构成的新型脂质体,包封率高,可多途径给药,且具有良好的缓释作用,目前已在抗肿瘤药物、镇痛药物、抗菌药物、抗病毒药物和蛋白质多肽药物上广泛运用。但如今多囊脂质体在稳定性、贮存和运输等方面仍存在一些问题,相信随着对多囊脂质体研究的深入,其必将在递药系统中得到更广泛的运用。
Objective: To provide reference for the application of multivesicular liposomes in delivery system. METHODS: Using the “multivesicular liposomes” and “multivesicular liposomes” as the key words, the articles from 1983 to 2013 were searched in databases such as CNKI and Pub Med, and the multivesicular liposomes The carrier in the delivery system research summarized and summarized. RESULTS AND CONCLUSION: A total of 609 articles were found, of which 20 were valid. The analysis shows that the multi-capsular liposomes are non-concentric cavity composed of new liposomes, encapsulation efficiency, can be multi-channel administration, and has a good sustained-release effect, has been in the anti-tumor drugs, analgesics , Antibacterial drugs, antiviral drugs and protein peptides widely used drugs. However, there are still some problems in the stability, storage and transportation of multivesicular liposomes nowadays. It is believed that with the further research on multivesicular liposomes, it will be more widely used in the delivery system.